{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:30Z","timestamp":1787738970517,"version":"build-2784847793"},"reference-count":55,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission with first-line therapy, as well as in chemotherapy-sensitive relapse if allogeneic transplant is not an option. CD25 is a targetable protein often highly expressed in PTCLs. In this phase 1 clinical trial, we tested the addition of \u03b2-emitting 90yttrium (90Y)\u2013labeled chimeric anti-CD25 basiliximab (aTac) to BEAM (carmustine, etoposide, cytarabine, and melphalan) as conditioning for AHCT for patients with PTCL. Twenty-three AHCT-eligible patients were enrolled, and 20 received therapeutic 90Y-aTac-BEAM AHCT. Radiation doses of 0.4, 0.5, and 0.6 mCi\/kg were tested. With no observed dose-limiting toxicities, 0.6 mCi\/kg was deemed the recommended phase 2 dose. The most prevalent adverse effect, grade 2 mucositis, was experienced by 80% of patients. As of this report, 6 (30%) of the treated patients had died, 5 due to progressive disease and 1 due to multiple organ failure (median time of death, 17\u00a0months [range, 9-21]) after AHCT. Median follow-up was 24\u00a0months (range, 9-26) overall and 24\u00a0months (range, 13-26) for surviving patients. For patients who received therapeutic 90Y-aTac-BEAM AHCT, the 2-year progression-free and overall survival were 59% (95% confidence interval [CI], 34-77) and 68% (95%\u00a0CI, 42-84), respectively. 90Y-aTac-BEAM appears to be safe as an AHCT conditioning regimen for PTCL, with no increased toxicity over the toxicities historically seen with BEAM alone in this patient population. This trial was registered at www.ClinicalTrials.gov as #NCT02342782.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012497","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T18:55:55Z","timestamp":1717613755000},"page":"4812-4822","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-629X","authenticated-orcid":false,"given":"Jasmine","family":"Zain","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chun","family":"Tsai","sequence":"additional","affiliation":[{"name":"2Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"},{"name":"2Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Simpson","sequence":"additional","affiliation":[{"name":"3Clinical Trials Office, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-4349","authenticated-orcid":false,"given":"Vikram","family":"Adhikarla","sequence":"additional","affiliation":[{"name":"2Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Bading","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yazaki","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen P.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Dandapani","sequence":"additional","affiliation":[{"name":"5Department of Radiology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Y.","family":"Song","sequence":"additional","affiliation":[{"name":"6Department of Pathology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Karras","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn P.","family":"Nademanee","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-659X","authenticated-orcid":false,"given":"D. Lynne","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"8Department of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus K.","family":"Poku","sequence":"additional","affiliation":[{"name":"9Radiopharmacy, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Eric","family":"Biglang-Awa","sequence":"additional","affiliation":[{"name":"9Radiopharmacy, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Colcher","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-770X","authenticated-orcid":false,"given":"John E.","family":"Shively","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Wu","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wong","sequence":"additional","affiliation":[{"name":"5Department of Radiology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"11","key":"2024092413112429100_bib1","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024092413112429100_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"25","key":"2024092413112429100_bib3","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024092413112429100_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11912-010-0125-0","article-title":"Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?","volume":"12","author":"Casulo","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2024092413112429100_bib5","first-page":"92","article-title":"Hematopoietic stem cell transplant in aggressive T and NK\/T cell lymphoma - role of upfront autologous transplant in nodal peripheral T-cell lymphoma","volume":"4","author":"Cheng Kiat Ng","year":"2021","journal-title":"Blood Cell Ther"},{"issue":"3","key":"2024092413112429100_bib6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bjh.14130","article-title":"The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naive patients with peripheral T-cell lymphoma: a systematic review of the literature","volume":"178","author":"Jethwa","year":"2017","journal-title":"Br J Haematol"},{"key":"2024092413112429100_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-3-319-99716-2_13","volume-title":"T-Cell and NK-Cell Lymphomas: From Biology to Novel Therapies","author":"Zain","year":"2019"},{"issue":"7","key":"2024092413112429100_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024092413112429100_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2024092413112429100_bib10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","article-title":"A\u00a0comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi","volume":"24","author":"Olivieri","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024092413112429100_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17474086.2019.1583102","article-title":"New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination","volume":"12","author":"Ma","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2024092413112429100_bib12","first-page":"506","article-title":"IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases","volume":"126","author":"Strauchen","year":"1987","journal-title":"Am J Pathol"},{"issue":"6","key":"2024092413112429100_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0167-5699(93)90043-K","article-title":"The IL-2\/IL-2 receptor system: a target for rational immune intervention","volume":"14","author":"Waldmann","year":"1993","journal-title":"Immunol Today"},{"issue":"7","key":"2024092413112429100_bib14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.34281","article-title":"CD25: A potential tumor therapeutic target","volume":"152","author":"Peng","year":"2023","journal-title":"Int J Cancer"},{"issue":"6","key":"2024092413112429100_bib15","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci"},{"issue":"2","key":"2024092413112429100_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024092413112429100_bib17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024092413112429100_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin Immunol"},{"issue":"suppl 1","key":"2024092413112429100_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood-2022-166916","article-title":"Efficacy and safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302","volume":"140","author":"Foss","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024092413112429100_bib20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2018-99-115986","article-title":"Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed\/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma","volume":"132","author":"Collins","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2024092413112429100_bib21","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or\u00a0= 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024092413112429100_bib22","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/bloodadvances.2021004981","article-title":"Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024092413112429100_bib23","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A\u00a0phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2024092413112429100_bib24","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A\u00a0phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"24","key":"2024092413112429100_bib25","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1158\/1078-0432.CCR-09-1421","article-title":"A\u00a0phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma","volume":"15","author":"Dancey","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024092413112429100_bib26","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"issue":"4","key":"2024092413112429100_bib27","first-page":"249","article-title":"(90)Y-daclizumab (Anti-CD25), high-dose carmustine, etoposide, cytarabine, and melphalan chemotherapy and autologous hematopoietic stem cell transplant yielded sustained complete remissions in 4 patients with recurrent Hodgkin's lymphoma","volume":"35","author":"Conlon","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"42","key":"2024092413112429100_bib28","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.1516107112","article-title":"90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma","volume":"112","author":"Janik","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024092413112429100_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2011.07.016","article-title":"Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma","volume":"18","author":"Krishnan","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024092413112429100_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0360-3016(00)01373-0","article-title":"Long-term complications of total body irradiation in adults","volume":"49","author":"Thomas","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"2024092413112429100_bib31","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2024092413112429100_bib32","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"2024092413112429100_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HP.0000000000001682","article-title":"OLINDA\/EXM 2-the next-generation personal computer software for internal dose assessment in nuclear medicine","volume":"124","author":"Stabin","year":"2023","journal-title":"Health Phys"},{"issue":"5","key":"2024092413112429100_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024092413112429100_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024092413112429100_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","article-title":"Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies","volume":"6","author":"Dillman","year":"2006","journal-title":"Clin Exp Med"},{"issue":"1","key":"2024092413112429100_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"issue":"9","key":"2024092413112429100_bib38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024092413112429100_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl\u00a01","key":"2024092413112429100_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2021-145124","article-title":"The Echelon-2 trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) vs CHOP in frontline treatment of Pts with CD30-positive peripheral T-cell lymphoma","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2024092413112429100_bib41","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024092413112429100_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024092413112429100_bib43","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024092413112429100_bib44","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12185-022-03470-1","article-title":"The role of epigenetics in T-cell lymphoma","volume":"116","author":"Yamagishi","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"2024092413112429100_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"9","key":"2024092413112429100_bib48","first-page":"1507","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":""},{"issue":"19","key":"2024092413112429100_bib49","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2020009850","article-title":"Outcomes for PTCL: which pathway to success?","volume":"137","author":"Vose","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024092413112429100_bib50","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/j.prro.2020.03.006","article-title":"Estimation of radiation-induced, organ-specific, secondary solid-tumor occurrence rates with total body irradiation and total marrow irradiation treatments","volume":"10","author":"Han","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2024092413112429100_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"12 Pt 1","key":"2024092413112429100_bib52","first-page":"6223","article-title":"Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies","volume":"46","author":"Badger","year":"1986","journal-title":"Cancer Res"},{"issue":"11","key":"2024092413112429100_bib53","doi-asserted-by":"crossref","first-page":"916","DOI":"10.7326\/0003-4819-132-11-200006060-00012","article-title":"Emerging immunotherapies for non-Hodgkin lymphomas: the tortoise approaches the finish line","volume":"132","author":"Press","year":"2000","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024092413112429100_bib54","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2023.2210710","article-title":"[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies","volume":"64","author":"Laszlo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2024092413112429100_bib55","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood-2021-146990","article-title":"CD70 expression in mature T-cell lymphomas","volume":"138","author":"Marques-Piubelli","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024092413112429100_bib56","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2024092413112429100_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11899-012-0124-3","article-title":"Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas","volume":"7","author":"Tobinai","year":"2012","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4812\/2243799\/blooda_adv-2023-012497-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4812\/2243799\/blooda_adv-2023-012497-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:56:48Z","timestamp":1727186208000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4812\/516360\/Yttrium-90-anti-CD25-BEAM-conditioning-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":55,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012497","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}